Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous HBV)-specific TCR-T therapy, ...